ClinicalTrials.gg
RecruitingNCT07123649I-MAMMOUpdated Apr 22, 2026

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

A Phase 2 interventional study of Shared Decision-Making Toolkit in Breast Cancer, sponsored by Dana-Farber Cancer Institute. Recruiting at 1 site in United States. Open to female participants aged 80 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
364
Allocation
Randomized
Ages
80 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute — 15 open to participants now, 43 under way, none of them phase 3. Breast Neoplasms · Dana-Farber Cancer Institute.

Planned enrollment
13th of 132
364 · median 50
Started
2025
with 3 others
Phase 2
56 of 142
7 open now
Primary completion
2027-09
later than 27 of 42 live
Registered
136th of 142
by date

Among the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, this one is the 13th largest by planned enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2025, is one of 56 in phase 2, reaches primary completion later than 27 of the 42 other live ones, and was the 136th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 80 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.

Read the detailed description

This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.

A participant will be placed into one of two groups: Group A: Usual Care vs. Group B: SDM Toolkit according to the randomized placement of the assigned study clinician.

Study procedures include questionnaires and option interviews with study staff.

Participation in this research study is expected to last about 2 years.

It is expected about 52 clinicians and 312 participants will take part in this research study.

The National Institute on Aging is providing funding for this research study

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Breast Cancer Survivor
  • Breast Cancer Survivorship
04

Who can participate

Ages eligible
80 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Participant Inclusion Criteria:

  • Women aged ≥ 80 years at the time of registration
  • History of stage 0-III breast cancer (Of note: ductal carcinoma in situ [DCIS], pleomorphic lobular carcinoma in situ [because it is typically treated like DCIS], or invasive breast cancer of any subtype are all eligible)
  • No history of a recurrent breast cancer (i.e., a breast cancer that is deemed or a locoregional recurrence of a prior cancer per clinician judgement rather than a new primary breast cancer). If a person has been diagnosed with multiple distinct breast cancers over time (e.g., history of left and right breast cancer), they are eligible as long as they meet other requirements for time since surgery, etc.
  • Has at least one intact breast
  • Has had mammogram screening/surveillance within the last 24 months

    -≥ 12 months since most recent breast surgery to affected breast (e.g., breast reduction surgery on an unaffected breast within 12 months is ok)

  • No active cancer-directed therapy other than hormonal therapy and/or CDK 4/6 inhibitor therapy
  • Ability and willingness to take surveys
  • Receiving at least some of their oncology follow-up care at a participating site
  • Most recent mammogram report for the potential participant did not recommend additional diagnostic work-up or close interval follow-up imaging

    • If a patient required diagnostic breast testing in the past or at the time of the most recent mammogram AND the results were resolved to benign findings with no additional diagnostics recommended, they are eligible.
    • If a patient's most recent mammogram result isn't yet available at the time of approach or study consent, the patient is eligible to proceed with consent and enrollment. If this mammogram then abnormal or requires additional imaging, that patient will not be included in the study analyses or surveys. This patient will be replaced.

Participant Exclusion Criteria:

  • Inability to provide
  • Assigned male sex at birth
  • Breast or recent imaging findings requiring diagnostic testing at baseline
  • Prior discontinuation of mammography by electronic medical record (EMR) review or patient report
  • Prior atypical ductal hyperplasia (ADH) or non-pleomorphic LCIS only
  • Psychiatric illness situations that would limit compliance with study requirements
  • Those with metastatic breast cancer
  • Those in hospice care
  • Those whose clinician is not willing to participate
  • Pregnant women, young patients, and those in prison will not be eligible for enrollment given the study design and aims supporting study in a different population focused on older adults

Clinician Inclusion Criteria:

  • Must be an active clinician (MD, NP, or PA) at a participating institution
  • Sees at least one breast-cancer survivor aged ≥ 80
  • Clinician must be able to read, speak, and write in English
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
364 participants (estimated)

Study arms

  • Experimental
    Shared-Decision Making Toolkit

    Enrolled participants will complete: * Year 1 standard of care visit with clinician followed by post-visit survey * Optional semi-structured interview with study staff * Year 2 standard of care visit with clinician followed by post-visit survey * Optional semi-structured interview with study staff * End of study survey

    Behavioral: Shared Decision-Making Toolkit

  • No intervention
    Usual Care

    Enrolled participants will continue with standard care practices without the SDM toolkit and will complete: * Year 1 standard of care visit with clinician followed by post-visit survey * Year 2 standard of care visit with clinician followed by post-visit survey * Optional semi-structured interview with study staff

Interventions

  • BehavioralShared Decision-Making Toolkit

    The SDM toolkit is designed to support discussions on the continuation of surveillance mammography. It provides evidence-based guidelines, communication strategies, and education materials to aid in personalized decision-making.

    Also known as: SDM Toolkit

06

What researchers measure

Primary outcomes

  1. Mammography Rate

    Mammography Rate is defined as the proportion of participants that undergo mammography by 2 years post-enrollment.

    Time frame: Assessed at 2 years post-enrollment.

Secondary outcomes

  1. Mammography Count

    Mammography Count is defined as the count of all mammograms each participant underwent during study follow-up.

    Time frame: Assessed at 2 years post-enrollment.

  2. Participant Knowledge Score

    Participant Knowledge Score will be defined as the proportion of correct knowledge questions (range: 0 to 1).

    Time frame: Annually through 2 years of follow-up post-enrollment.

  3. Participant Decisional Quality Score

    Participant Decisional Quality Score will be defined as the sum of response scores (range of 0-4), with each individual response scored 0 or 1. Higher scores indicate higher decisional quality.

    Time frame: Annually through 2 years of follow-up post-enrollment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 24 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 14, 2025
StartActual
Sep 11, 2025
Primary completionEst.
Sep 11, 2027
CompletionEst.
Sep 11, 2029
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07123649
Responsible party
Rachel Freedman, MD, MPH (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Aug 14, 2025
Start date
Sep 11, 2025
Primary completion
Sep 11, 2027 (estimated)
Completion
Sep 11, 2029 (estimated)
Last update
Apr 22, 2026

Study contacts

Rachel Freedman, MD, MPH
Contact
Rachel_freedman@dfci.harvard.edu
617-632-4587
Rachel Freedman, MD, MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion